上海益诺思生物技术股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688710 证券简称：益诺思 公告编号：2025-043 （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 公司董事长魏树源先生以线上方式参会，经半数以上董事推举，由公司董事 常艳女士主持本次股东大会。本次股东大会采用现场投票与网络投票相结合的表 决方式进行表决。本次会议的召集、召开符合《公司法》《公司章程》《股东会规 则》等法律、法规和规范性文件的规定。 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事9人，出席9人； 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 28 日 （二） 股东大会召开的地点：中国（上海）自由贸易试验区郭守敬路 199 号 105 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东 ...

上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 国浩律师（上海）事务所 关于上海益诺思生物技术股份有限公司 北京 上海 深圳 杭州 广州 昆明 天津 成都 宁波 福州 西安 南京 南宁 济南 香港 巴黎 马德里 硅谷 BEIJING SHANGHAI SHENZHEN HANGZHOU GUANGZHOU KUNMING TIANJIN CHENGDU NINGBO FUZHOU XI'AN NANJING NANNING JINAN HONG KONG PARIS MADRID SILICON VALLEY 2025 年第四次临时股东大会的 法律意见书 致：上海益诺思生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《 ...

人民财讯11月28日电，益诺思(688710)11月28日公告，持股7.82%的股东张江生药基地拟减持公司股份 不超过140.98万股(占公司总股本的比例不超过1%)。 ...

格隆汇11月28日丨益诺思(688710.SH)公布，张江生药基地计划自本公告披露之日起15个交易日后的3个 月内，通过集中竞价交易方式减持其所持有的公司股份数量不超过140.98万股，占公司总股本的比例不 超过1.00%，且在任意连续90个自然日内，减持的股份总数不超过公司股份总数的1.00%。减持价格按 市场价格确定。 ...

Core Viewpoint - The shareholder Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. plans to reduce its stake in Yinuo through a concentrated bidding process, indicating a strategic move for operational development needs [1] Shareholder Information - Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. holds 11.02 million shares, representing 7.82% of the total shares [1] - The planned reduction involves selling up to 1.4098 million shares, which accounts for 1.00% of the total shares [1] Reduction Timeline - The reduction period is set from December 22, 2025, to March 20, 2026 [1] - The selling price will be determined based on market conditions [1] Regulatory Compliance - The shareholder is allowed to reduce no more than 1.00% of the total shares within any continuous 90-day period [1]

Market Overview - The medical services sector increased by 1.65% on November 24, with Chengdu XianDao leading the gains [1] - The Shanghai Composite Index closed at 3836.77, up 0.05%, while the Shenzhen Component Index closed at 12585.08, up 0.37% [1] Stock Performance - Notable stock performances include: - Chengda Pharmaceutical (301201) closed at 46.40, down 3.25% with a trading volume of 129,800 shares and a turnover of 613 million yuan - Yaner Eye Hospital (300015) closed at 11.55, down 1.20% with a trading volume of 684,000 shares and a turnover of 797 million yuan - International Medical (000516) closed at 4.65, up 0.87% with a trading volume of 119,800 shares and a turnover of 55.6 million yuan [1] Capital Flow - The medical services sector experienced a net outflow of 170 million yuan from institutional investors and 158 million yuan from retail investors, while retail investors saw a net inflow of 327 million yuan [3] - Key capital flows for specific stocks include: - WuXi AppTec (603259) had a net inflow of 251 million yuan from institutional investors but a net outflow of 91.72 million yuan from retail investors - Tiger Med (300347) saw a net inflow of 62.56 million yuan from institutional investors but a net outflow of 6.44 million yuan from retail investors [3]

Group 1 - The core viewpoint of the news is that Yinosh has experienced a decline in both revenue and net profit, indicating potential challenges in its business performance [2] - As of November 20, Yinosh's stock price increased by 0.69%, with a trading volume of 57.54 million yuan, while the net financing buy was negative at -397,600 yuan [1] - The financing balance of Yinosh is 59.99 million yuan, which accounts for 1.43% of its market capitalization, indicating a low level compared to the past year [1] Group 2 - For the period from January to September 2025, Yinosh reported a revenue of 571 million yuan, a year-on-year decrease of 35.33%, and a net profit attributable to shareholders of -14.79 million yuan, a decline of 111.14% [2] - The number of shareholders decreased by 9.97% to 4,849, while the average circulating shares per person increased by 257.28% to 18,703 shares [2] - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, while several funds exited the top ten circulating shareholders list [2]

Core Viewpoint - The domestic R&D demand is showing marginal improvement, driven by the overseas expansion of innovative drugs, leading to a recovery in R&D orders and stabilization of industry prices after a decline in 2023. The CRO sector is expected to see better performance growth by 2026, while the CDMO industry has also reached a bottom and is poised for continued strong growth due to robust demand for new molecules and new orders [1][2][3]. CRO Sector - The domestic R&D demand is recovering, with an increase in orders and stabilization of prices, indicating a clear upward trend for CRO companies. Clinical CROs like Tigermed, Nossan, and Prasis are expected to see revenue growth turning positive by 2025, with significant contributions from overseas business [2][3]. - The recognition of domestic CRO clinical data is improving, which is beneficial for companies like Tigermed [2]. CDMO Sector - The CDMO sector has seen a recovery in performance, with new orders continuing to improve quarterly. The global demand for innovative drug R&D is driving growth in new orders and backlog [3]. - The industry is benefiting from increased capacity utilization and profitability, with a strong certainty of performance and profit growth expected to continue into 2026 [3]. Life Sciences Sector - The life sciences upstream sector is experiencing a dual drive from domestic substitution and overseas expansion, with urgent demand for domestic alternatives in areas like cell culture media and biological reagents. Companies are expected to capture market share through new product categories and cost-effective offerings [4]. - The demand for specific segments such as drug efficacy, antibodies, and proteins is increasing, indicating a clear long-term growth logic for the industry [4]. API Sector - The raw material pharmaceutical industry is currently in a phase of price bottoming and supply surplus, with traditional product performance under pressure. However, companies are extending their business into generics, innovative drugs, and specialty APIs, which may lead to value reconstruction through business structure optimization [5]. - The valuation of raw material pharmaceutical companies is at a low point, presenting opportunities based on changes in new business layouts [5]. Investment Recommendations - For clinical and preclinical CROs, companies like Tigermed, Nossan, and Yinos are recommended due to the gradual recovery of the industry and expected improvement in order structure [6]. - In the CDMO sector, companies such as WuXi AppTec, WuXi Biologics, and others with strong fundamentals and capacity advantages are highlighted for their potential benefits from industry recovery and high demand for new molecules [6]. - In the life sciences upstream sector, companies like Baitai Biotechnology and others are recommended due to accelerated domestic substitution and strong overseas growth [6]. - Companies like Pro Pharma and Huahai Pharmaceutical are noted for their new business layouts that are expected to contribute significant value increments [6].

Core Viewpoint - Yinosh's stock price has experienced fluctuations, with a year-to-date increase of 28.73% but a recent decline of 9.40% over the past five trading days, indicating volatility in investor sentiment and market conditions [1]. Company Overview - Yinosh Biotechnology Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company specializes in providing non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services [1]. - The company was listed on September 3, 2024, and operates primarily in the medical biology sector, focusing on medical research outsourcing [1]. Financial Performance - As of September 30, 2025, Yinosh reported a revenue of 571 million yuan, a year-on-year decrease of 35.33%. The net profit attributable to shareholders was -14.79 million yuan, reflecting a significant decline of 111.14% compared to the previous period [2]. - The company has distributed a total of 45.11 million yuan in dividends since its A-share listing [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 9.97% to 4,849, while the average number of circulating shares per person increased by 257.28% to 18,703 shares [2]. - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, which are now among the top ten circulating shareholders [3].

Core Viewpoint - Yinos's stock price has experienced fluctuations, with a year-to-date increase of 32.48% but a recent decline of 7.04% over the past five trading days [1] Group 1: Stock Performance - As of November 18, Yinos's stock price was 46.62 CNY per share, with a market capitalization of 6.572 billion CNY [1] - The stock has seen a trading volume of 16.86 million CNY and a turnover rate of 0.39% [1] - The stock's performance over various periods includes a 11.13% increase over the last 20 days and a 6.17% increase over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Yinos reported a revenue of 571 million CNY, reflecting a year-on-year decrease of 35.33% [2] - The company recorded a net profit attributable to shareholders of -14.79 million CNY, a decline of 111.14% year-on-year [2] - Cumulative cash dividends paid since the A-share listing amount to 45.11 million CNY [2] Group 3: Shareholder Information - As of September 30, 2025, the number of Yinos's shareholders was 4,849, a decrease of 9.97% from the previous period [2] - The average number of circulating shares per shareholder increased by 257.28% to 18,703 shares [2] - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, while several funds exited the top ten shareholders list [2]